The launch of the 750mcg parathyroid hormone solution in Australia has encountered restricted distribution . Currently, this larger dose medication is mainly designated for people with significant osteoporosis who have been unsuccessful with other medications. Access can be difficult due to physician approval requirements and controlled dispensary